Clinical trials: Relapsed/ Refractory Multiple Myeloma
Multiple Myeloma
A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Multiple myeloma (MM) is a neoplastic plasma cell disorder that is characterized by osteolytic bone lesions, anemia, hypercalcemia and renal failure.
- Trial name
- NCT04177823
- Testing
- Belantamab mafodotin
- Where
- China
- Volunteers
- 6 people
- Sponsor
- GlaxoSmithKline
Leukemia, Lymphoma
Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as melphalan and fludarabine, and a monoclonal antibody, such as alemtuzumab, before a donor bone marrow or peripheral blood stem cell transplant helps stop the growth of cancer…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00027560
- Testing
- alemtuzumab, cyclosporine, fludarabine phosphate
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy. Sometimes the transplanted cells from a donor are rejected by the body's normal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00068523
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Case Comprehensive Cancer Center
Multiple Myeloma
A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma
This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 in combination with a multiple myeloma (MM)-targeting monoclonal antibody capable of inducing antibody-dependent cellular toxicity…
- Trial name
- NCT05243342
- Testing
- XmAb24306, Daratumumab
- Where
- 7 sites in Australia, Denmark and 2 more
- Volunteers
- 18 people
- Sponsor
- Genentech, Inc.
Multiple Myeloma
Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma
The current study is being conducted to evaluate the possibility that a different schedule of bortezomib, doxorubicin HCl liposome, and dexamethasone might decrease the incidence of peripheral neuropathy yet maintain similar…
- Trial name
- NCT00366106
- Testing
- bortezomib, dexamethasone, doxorubicin HCl liposome
- Where
- 15 sites in United States
- Volunteers
- 32 people
- Sponsor
- Accelerated Community Oncology Research Network
Relapsed/Refractory Multiple Myeloma
UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
The clinical trial was designed as a single-arm, open-label clinical study, with the main purpose of exploring the safety, pharmacokinetics, and best recommended dose (RP2D) of the UTAA17 injection in the treatment of relapsed or…
- Trial name
- NCT06279026
- Testing
- UTAA17 Injection
- Where
- China
- Volunteers
- 15 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Multiple Myeloma
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of…
- Trial name
- iMMagine-3 (NCT06413498)
- Testing
- Anitocabtagene Autoleucel, Cyclophosphamide, Fludarabine
- Where
- 117 sites in United States, Australia and 13 more
- Volunteers
- 452 people
- Sponsor
- Kite, A Gilead Company
Myeloma
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
The purpose of this study is to see if the combination of bendamustine, lenalidomide and dexamethasone will help people with multiple myeloma that has returned after standard treatment or has been resistant to other treatments.
- Trial name
- NCT01042704
- Testing
- Bendamustine, Lenalidomide, Dexamethasone
- Where
- 22 sites in United States
- Volunteers
- 29 people
- Sponsor
- Robert Redner, MD
Relapsed/Refractory Multiple Myeloma
A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to assess in real-life clinical practice, over a 24-month period, the effectiveness and safety and patient-reported outcomes (PROs) associated with standard of care (SOC) antimyeloma treatments in…
- Trial name
- MoMMent (NCT05160584)
- Testing
- No intervention
- Where
- 90 sites in Austria, Belgium and 10 more
- Volunteers
- 300 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Multiple Myeloma
Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Open-label, dose escalation study to evaluate the safety, tolerability, pharmacokinetics (PK)/pharmacodynamics and initial efficacy of AO-176 as monotherapy and in combination with dexamethasone and bortezomib in adults with…
- Trial name
- NCT04445701
- Testing
- AO-176, AO-176 + Dex, AO-176 + Dex + Bort
- Where
- 6 sites in United States
- Volunteers
- 10 people
- Sponsor
- Arch Oncology
Relapsed or Refractory Multiple Myeloma
Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma
The investigators will perform a phase I/II trial of Revlimid daily for 21 days and Abraxane weekly for 3 weeks. Accrual will be on standard cohorts of 3 patients.
- Trial name
- rev/abraxane (NCT02075021)
- Testing
- Lenalidomide, nab-paclitaxel
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- NYU Langone Health
Relapse/Refractory Multiple Myeloma
Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the efficacy and safety of paclitaxel in combination with cyclophosphamide and dexamethasone in chinese patients with relapsed/refractory multiple myeloma.
- Trial name
- NCT02985333
- Testing
- Paclitaxel, Cyclophosphamide, Dexamethasone
- Where
- China
- Sponsor
- Sun Yat-sen University
Breast Cancer, Chronic Myeloproliferative Disorders
Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors
RATIONALE: Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer
- Trial name
- NCT00003107
- Testing
- recombinant interleukin-12
- Where
- United States
- Sponsor
- Indiana University
Relapsed or Refractory Multiple Myeloma
CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma
This study is aimed to evaluate the safety, feasibility and efficacy of CAR-T cell therapy in the treatment of relapsed or refractory multiple myeloma
- Trial name
- NCT04626752
- Testing
- BCMA CAR-T, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Multiple Myeloma, Patient Participation
Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma
The median overall survival (OS) of relapsed/refractory multiple myeloma (MM) is less than nine months. However, phase II data with the proteasome inhibitor bortezomib (Velcade®) has been heartening, with 35% overall response…
- Trial name
- DMV (NCT00985907)
- Testing
- Doxil, melphalan, bortezomib
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- University of California, San Francisco
Relapsed or Refractory Hematologic Malignancies, Leukemia
A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies
The goal of this clinical trial is to learn about the safety, tolerability and preliminary effectiveness of a treatment for patients with relapsed or refractory hematologic malignancies, regardless of gender, aged between…
- Conditions
- Relapsed or Refractory Hematologic Malignancies, Leukemia, Lymphoma, Multiple Myeloma (MM)
- Trial name
- NCT07107204
- Testing
- BT02
- Volunteers
- 116 people
- Sponsor
- Biotroy Therapeutics
Multiple Myeloma and Plasma Cell Neoplasm
Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
RATIONALE: Drugs used in chemotherapy, such as hydroxychloroquine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00568880
- Testing
- bortezomib, hydroxychloroquine
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present
TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma
This phase I trial studies the side effects of NY-ESO-1 TCR engineered peripheral blood mononuclear cells (PBMC) and peripheral blood stem cells (PBSC) after melphalan conditioning regimen in treating participants with multiple…
- Conditions
- HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Trial name
- NYSCT MM (NCT03506802)
- Testing
- 18F-FHBG, Aldesleukin, Cellular Therapy
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Multiple Myeloma
Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma
Patients with myeloma that has either not responded to previous treatment or has returned after previous treatment will be given a combination of the drugs bendamustine and bortezomib.
- Trial name
- NCT01315873
- Testing
- Bendamustine, Bortezomib
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- NYU Langone Health
Relapsed/Refractory Multiple Myeloma
A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma
This is a Phase I/II, single-arm, open-label, multicenter clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM).
- Trial name
- NCT07760454
- Testing
- CT0596
- Where
- 2 sites in China
- Volunteers
- 68 people
- Sponsor
- UCARsgen Biotech Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.